Janney Montgomery Scott LLC Increases Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Janney Montgomery Scott LLC increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 39.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 2,079,281 shares of the company's stock after buying an additional 588,295 shares during the quarter. Janney Montgomery Scott LLC owned 0.18% of Teva Pharmaceutical Industries worth $31,959,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. IFP Advisors Inc lifted its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the topic of a number of recent research reports. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $24.44.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA traded down $0.09 on Friday, hitting $16.97. The stock had a trading volume of 10,762,752 shares, compared to its average volume of 10,257,119. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. The company has a market capitalization of $19.46 billion, a price-to-earnings ratio of -14.75, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The firm has a 50-day moving average of $16.39 and a 200-day moving average of $17.42.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same period in the prior year, the company posted $0.48 EPS. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.